

Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025

<https://marketpublishers.com/r/SBB581518884EN.html>

Date: August 2020

Pages: 250

Price: US\$ 3,600.00 (Single User License)

ID: SBB581518884EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025' Report highlight:

Diabetes Drug Market Opportunity: > US\$ 1.5 Billion by 2025

Diabetes Device Market Opportunity: > US\$ 1 Billion by 2025

Glucose Monitoring Device Market Absolute Growth: 33% (2019-2025)

Oral Hypoglycemic Drugs Market - Availability, Dosage & Price Analysis

Insulin Availability, Dosage & Price Analysis

Insulin Delivery Device Market - Availability, Price & Sales Analysis

Glucose Monitoring Device Market - Availability & Price Analysis

Investments & Collaborations by Leading Market Players

Over the past few years, Saudi Arabia has witnessed exponential economic growth and fortune, which is followed by the swift technological transformation that resulted in major undesirable effects on lifestyle. Consequently, the prevalence of physical inactivity, obesity and sedentary behaviors along with the consumption of high caloric diet, and

sugar-sweetened beverages went on the increase and became very common among Saudi society.

The diabetes incidences are increasing rapidly among the kingdom population and the same is expected to remain consistent in upcoming year due to presence of high percentage of obese and overweight population. Unhealthy lifestyle and lack of physical activities are two major factors responsible for the development of diabetes at early age in Saudi Arabian children and it is further observed that the prevalence rate of juvenile diabetes has been increasing continuously during the past few years. Driven by above mentioned factors, the diabetic burden in Saudi Arabia is expected to increase with higher momentum in future, which will ultimately lead to exponential demand of antidiabetic drugs there by driving the overall diabetes drug and insulin delivery market in coming years.

Several different initiatives and programs are undertaken by the regulatory bodies for supporting the diabetic patients in Saudi Arabia. Increasing diabetes patients, drug development in the field of diabetes, presence of generic drugs, government support, technological advancement, rising geriatric population, rising awareness and increasing healthcare and expenditure are the factors that are driving the diabetes market. The pipeline that the country's research and development center is holding is expected to double the market size at tremendous rate in the near future. Already the market is flooded with several branded and generic diabetes drugs and soon it will be joined by another large numbers of promising diabetes drugs. Various stake holders of the Saudi Arabia diabetes market are constantly working on the best possible treatment therapies for the diabetic population. To accompany this, the government has also started some healthcare missions that aims at providing the best healthcare solution to the patients who are in the urgent need of a treatment or who have failed earlier treatments. This whole covers a larger portion of the diabetes mellitus patients as a big part of the mission covers arrival of generic drug makers in the country and focusing towards the disease that are observed in larger percentage.

The diabetic population has widely accepted the presence of branded and imported drugs in the country driven by the socio economic parameters, which are apparently leading to accelerating growth of the branded diabetes drugs market in the country. In addition to the presence of branded drugs, the market is also observing an increase in the number of home grown pharmaceutical companies and distributors engaged in research, development and distribution of diabetes drugs in the market.

As per the report findings, it is estimated that soon the market will flourish in all the

parameters that are important for a market to dominate the entire diabetes market. Strong brand loyalty and increasing lifestyle diseases are some of the factors that are expected to drive the diabetes drug market in the upcoming timeframe. Furthermore, the country is experiencing growing healthcare infrastructure, increasing per capita income and a large influx of health insurance companies which are estimated to fuel the growing diabetes market. Such huge penetration of the parameters responsible for market growth is estimated to develop a strong and competitive landscape for the future diabetes market.

Contents

1. INTRODUCTION TO SAUDI ARABIA DIABETES MARKET

- 1.1 Overview
- 1.2 Current Market Scenario

2. SAUDI ARABIA - DIABETES PREVALENCE & STATISTICS

- 2.1 By Population
- 2.2 By Diabetes Type
 - 2.2.1 Type 1 Diabetes
 - 2.2.2 Type 2 Diabetes
- 2.3 By Age & Gender
- 2.4 Obesity & Overweight

3. SAUDI ARABIA - PHARMACEUTICAL PRICING & REIMBURSEMENT POLICIES

- 3.1 Pricing Policies
 - 3.1.1 In-Patent Pharmaceuticals
 - 3.1.2 Off-Patent, Generics & Other Locally Manufactured Product
- 3.2 Procurement & Reimbursement Policies

4. SAUDI ARABIA - REGULATORY ASPECTS OF PHARMACEUTICAL PRODUCTS

- 4.1 Gulf Central Committee for Drug Registrations (GCC-DR)
- 4.2 Regulatory Review Process
- 4.3 Centralized Registration
- 4.4 Decentralized Drug Registration Regulation

5. SAUDI ARABIA - DIABETES DRUG MARKET

- 5.1 Market Analysis
- 5.2 Prescription Pattern

6. SAUDI ARABIA - ORAL HYPOGLYCEMIC DRUGS MARKET - AVAILABILITY, DOSAGE & PRICE ANALYSIS

- 6.1 Biguanides (Metformin Hydrochloride)

- 6.1.1 Glucophage
- 6.1.2 Glucare XR
- 6.1.3 Dimetor
- 6.1.4 Formit XR
- 6.2 Sulfonylurea
 - 6.2.1 Gliclazide
 - 6.2.2 Glimepiride
 - 6.2.3 Glibenclamide
- 6.3 DPP-4 Inhibitors
 - 6.3.1 Vildagliptin
 - 6.3.2 Saxagliptin (Onglyza)
 - 6.3.3 Sitagliptin (Januvia)
- 6.4 SGLT2 Inhibitors
 - 6.4.1 Canagliflozin (Invokana)
 - 6.4.2 Dapagliflozin (Forxiga)
 - 6.4.3 Empagliflozin (Jardiance)
- 6.5 Others
 - 6.5.1 Meglitinides
 - 6.5.2 Thiazolidinediones
 - 6.5.3 α -Glucosidase Inhibitors
- 6.6 Combinational Drugs
 - 6.6.1 Metformin & Sulfonylurea Combination
 - 6.6.2 Metformin & DPP-4 Inhibitors Combination
 - 6.6.3 Metformin & SGLT-2 Inhibitors Combination

7. SAUDI ARABIA INSULIN MARKET - AVAILABILITY, DOSAGE & PRICE ANALYSIS

- 7.1 Lantus
- 7.2 Humulin
 - 7.2.1 Humulin 70/30 100U/ml
 - 7.2.2 Humulin N-NPH
- 7.3 Humalog
- 7.4 Mixtard
- 7.5 Apidra
- 7.6 Insulatard

8. SAUDI ARABIA - DIABETES DEVICE MARKET ANALYSIS

9. SAUDI ARABIA INSULIN DELIVERY DEVICE MARKET - AVAILABILITY, PRICE & SALES ANALYSIS

- 9.1 Insulin Syringes
- 9.2 Insulin Pen
 - 9.2.1 Humalog KwikPen
 - 9.2.2 Flexpen
 - 9.2.3 Solostar
 - 9.2.4 NovoPen
 - 9.2.5 Others
- 9.3 Insulin Pumps
- 9.4 Insulin Jet Injectors

10. SAUDI ARABIA - GLUCOSE MONITORING DEVICE MARKET - AVAILABILITY & PRICE ANALYSIS

- 10.1 Self-Monitoring Blood Glucose Devices
- 10.2 Continuous Glucose Monitoring Device

11. SAUDI ARABIA DIABETES MARKET – CLINICAL INSIGHT

12. SAUDI ARABIA DIABETES MARKET - INVESTMENTS & COLLABORATIONS BY LEADING MNCS

13. SAUDI ARABIA DIABETES MARKET DYNAMICS

- 13.1 Market Drivers
- 13.2 Challenges for Saudi Arabia Diabetes Market

14. SAUDI ARABIA DIABETES DRUG MARKET FUTURE OUTLOOK

15. COMPETITIVE LANDSCAPE

- 15.1 Abbott
- 15.2 Aljazeera Pharmaceutical Industries
- 15.3 Al Mojil Drug Company
- 15.4 AstraZeneca
- 15.5 Bayer
- 15.6 CAD Middle-East Pharmaceutical Company

- 15.7 Eli - Lilly
- 15.8 Julphur Pharmaceuticals
- 15.9 Kuwait Saudi Pharmaceutical Company
- 15.10 Merck
- 15.11 Novartis
- 15.12 Oman Pharmaceuticals
- 15.13 Roche
- 15.14 Saja Pharmaceuticals
- 15.15 Sanofi
- 15.16 Servier
- 15.17 SPIMACO Addwaeih
- 15.18 Tabuk Pharmaceuticals
- 15.19 Qatar Life Pharma
- 15.20 YIACO Medical Company

List Of Figures

LIST OF FIGURES

- Figure 1-1: Adult Diabetic Population - MEA v/s Saudi Arabia (Million), 2019
- Figure 1-2: Adult Diabetic Population - Saudi Arabia v/s Rest of MEA (%), 2019
- Figure 1-3: Adult Diabetic Population - GCC v/s Saudi Arabia (Million), 2019
- Figure 1-4: Adult Diabetic Population - Saudi Arabia v/s Rest of GCC (%), 2019
- Figure 1-5: Saudi Arabia Healthcare Expenditure - Total v/s Diabetes (US\$ Billion), 2018
- Figure 1-6: Saudi Arabia Healthcare Expenditure - Diabetes v/s Other Diseases (%), 2018
- Figure 1-7: Middle East - Diabetes Drug Market Opportunity (US\$ Billion), 2019-2025
- Figure 1-8: Middle East v/s Saudi Arabia - Diabetes Drug Market Size (US\$ Billion), 2019
- Figure 1 9: Saudi Arabia - Diabetes Device Market Size - Total v/s Blood Glucose Monitoring Device (US\$ Million), 2019
- Figure 2-1: Saudi Arabia - Adult Diabetic Population (Million), 2017 & 2019
- Figure 2-2: Saudi Arabia - Estimated Number of Adult Diabetic Population (Million), 2030 & 2045
- Figure 2-3: Saudi Arabia Adult Diabetic Population - Diagnosed v/s Undiagnosed (Million), 2019
- Figure 2-4: Saudi Arabia - Adult Diabetic Population Share - Diagnosed v/s Undiagnosed (%), 2019
- Figure 2-5: Saudi Arabia - Population Estimates (Million), 2019, 2020, 2025 & 2030
- Figure 2-6: Saudi Arabia Population by Age (Million), 2019
- Figure 2-7: Saudi Arabia - Adult Population (Million), 2019, 2030 & 2045
- Figure 2-8: Saudi Arabia - Age Adjusted Diabetes Prevalence Rate (%), 2019, 2025 & 2045
- Figure 2-9: Saudi Arabia - Diabetes Related Deaths, 2010 & 2019
- Figure 2-10: Saudi Arabia - Adult Diabetes Cases by Type (Million), 2019
- Figure 2-11: Saudi Arabia - Diabetes Cases by Type (%), 2019
- Figure 2-12: Saudi Arabia - Type 1 Diabetic Adult Population (Million), 2019, 2025 & 2045
- Figure 2-13: Saudi Arabia - Total & Newly Diagnosed Type 1 Diabetic Cases in Age below 19 Years, 2019
- Figure 2-14: Saudi Arabia - Type Diabetic Population (Million), 2019, 2025 & 2045
- Figure 2-15: Saudi Arabia - Diabetes Prevalence Rate by Gender (%), 2016
- Figure 2-16: Saudi Arabia - Diabetic Population by Gender (Million), 2016

Figure 2-17: Saudi Arabia - Diabetes Cases by Age (%), 2017

Figure 2-18: Saudi Arabia - Newly Diagnosed Type 1 Diabetes Cases in Children by Age, 2019

Figure 2-19: Saudi Arabia - Type 1 Diabetes Cases in Children by Age, 2019

Figure 2-20: Saudi Arabia - Type 1 Diabetes Cases in Children by Age (%), 2019

Figure 2-21: Saudi Arabia - Obesity Prevalence Rate (%), 2016 & 2019

Figure 2-22: Saudi Arabia - Obese Population (Million), 2016 & 2019

Figure 2-23: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2016

Figure 2-24: Saudi Arabia - Overweight Prevalence Rate by Gender (%), 2016

Figure 2-25: Saudi Arabia - Physical Inactivity Prevalence Rate by Gender (%), 2016

Figure 4-1: Saudi Arabia - Types of Drug Registration Process

Figure 4-2: Process Map for GCC Centralized Registration

Figure 4-3: GCC – Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US\$), 2019

Figure 4-4: GCC – Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US\$), 2019

Figure 4-5: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US\$), 2019

Figure 4-6: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US\$), 2019

Figure 4-7: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US\$), 2019

Figure 4-8: Saudi Arabia – Regulatory Process for Pharmaceuticals

Figure 5-1: Saudi Arabia - Diabetes Drug Market Size (US\$ Million), 2019 - 2025

Figure 5-2: Saudi Arabia - Patients on Single, Double & Triple Drug Therapy for Diabetes Management (%), 2018

Figure 5-3: Saudi Arabia - Prescription Share of Anti-Diabetic Drugs (%), 2018

Figure 5-4: Saudi Arabia - Sulfonylurea Drug's Prescription Share by products (%), 2018

Figure 5-5: Saudi Arabia - Insulin Prescription Share by Type (%), 2018

Figure 6-1: Metformin - Recommended Initial, Maintenance & Maximum Dose of Immediate Release Tablet for Adults (mg/day), January'2020

Figure 6-2: Metformin - Recommended Initial & Maximum Dose of Extended Release Tablet for Adults (mg/day), January'2020

Figure 6-3: Metformin - Recommended Initial & Maximum Dose of Immediate Release Tablet for Pediatrics (mg/day), January'2020

Figure 6-4: Metformin - Recommended Initial & Maximum Dose of Extended Release Tablet for Pediatrics (mg/day), January'2020

Figure 6-5: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 500mg

Glucophage Tablet (US\$/SAR), January'2020

Figure 6-6: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of 850mg

Glucophage Tablet (US\$/ SAR), January'2020

Figure 6-7: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of 1gm

Glucophage Tablet (US\$/ SAR), January'2020

Figure 6-8: Saudi Arabia - Price for 30, 60 & 90 Tablet Supply & Price per unit of 500mg

Glucare XR Tablet (US\$/SAR), January'2020

Figure 6-9: Saudi Arabia - Price for 30 & 60 Tablet Supply & Price per unit of 750mg

Glucare XR Tablet (US\$/SAR), January'2020

Figure 6-10: Saudi Arabia - Price for 60 Tablet Supply & Price per unit of 1000mg

Glucare XR Tablet (US\$/SAR), January'2020

Figure 6-11: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 500mg

Dimetor Tablet (US\$/SAR), January'2020

Figure 6-12: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 850mg

Dimetor Tablet (US\$/SAR), January'2020

Figure 6-13: Saudi Arabia - Price for 30 & 60 Tablet Supply & Price per unit of 750mg

Formit XR Tablet (US\$/SAR), January'2020

Figure 6-14: Gliclazide - Recommended Initial & Maximum Dose for Adults (mg/day),
January'2020

Figure 6-15: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Diamicon MR
Tablet (US\$/SAR), January'2020

Figure 6-16: Saudi Arabia - Price for 20 Tablet Supply & Price per unit Glaze 80mg
Tablet (US\$/SAR), January'2020

Figure 6-17 Saudi Arabia - Price for 60 Tablet Supply & Price per unit Glaze 80mg
Tablet (US\$/SAR), January'2020

Figure 6-18: Saudi Arabia - Price for 30 Tablet Supply & Price per unit Debacron 80mg
Tablet (US\$/SAR), January'2020

Figure 6-19: Glimpiride - Recommended Initial & Maximum Dose for Adults (mg/day),
January'2020

Figure 6-20: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of
Amaryl Tablet (US\$/SAR), January'2020

Figure 6-21: Saudi Arabia - Price per unit of Various Dose Regimen of Amaryl Tablet
(US\$/SAR), January'2020

Figure 6-22: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of Glim
Tablet (US\$/SAR), January'2020

Figure 6-23: Saudi Arabia - Price per unit of Various Dose Regimen of Glim Tablet
(US\$/SAR), January'2020

Figure 6-24: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of
Glorion Tablet (US\$/SAR), January'2020

Figure 6-25: Saudi Arabia - Price per unit of Various Dose Regimen of Glorion Tablet (US\$/SAR), January'2020

Figure 6-26: Glibenclamide - Recommended Minimum & Maximum Initial Dose for Adults (mg/day), January'2020

Figure 6-27: Glibenclamide - Recommended Minimum & Maximum Maintenance Dose for Adults (mg/day), January'2020

Figure 6-28: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Daonil Tablet (US\$/SAR), January'2020

Figure 6-29: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Glibil Tablet (US\$/SAR), January'2020

Figure 6-30: Saudi Arabia - Price for 100 Tablet Supply & Price per unit of Apo-Glyburide Tablet (US\$/SAR), January'2020

Figure 6-31: Vildagliptin - Recommended Dose in Combinational & Monotherapy for Type-2 Diabetes Treatment (mg/day), January'2020

Figure 6-32: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Galvus 50mg Tablet (US\$/SAR), January'2020

Figure 6-33: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Valdatin 50mg Tablet (US\$/SAR), January'2020

Figure 6-34: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Jalra 50mg Tablet (US\$/SAR), January'2020

Figure 6-35: Onglyza - Patent Issue & Expiration Year

Figure 6-36: Saxagliptin - Recommended Minimum & Maximum Daily Dose (mg/day), January'2020

Figure 6-37: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Onglyza 2.5mg Tablet (US\$/SAR), January'2020

Figure 6-38: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Onglyza 5mg Tablet (US\$/SAR), January'2020

Figure 6-39: Januvia - Patent Issue & Expiration Year

Figure 6-40: Saudi Arabia - Price for 28 Tablet Supply & Price per unit of Januvia 100mg Tablet (US\$/SAR), January'2020

Figure 6-41: Saudi Arabia - Monthly & Annual Treatment Cost of Type-2 Diabetes using Januvia Tablet (US\$/SAR), January'2020

Figure 6-42: Invokana - Patent Issue & Expiration Year

Figure 6-43: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Invokana Tablet (US\$/SAR), January'2020

Figure 6-44: Invokana - Recommended Minimum & Maximum Dose for Adults (mg/day), January'2020

Figure 6-45: Forxiga - Recommended Minimum & Maximum Dose for Adults (mg/day), January'2020

Figure 6-46: Saudi Arabia - Price for 28 Tablet Supply & Price per unit of Forxiga Tablet (US\$/SAR), January'2020

Figure 6-47: Jardiance - Patent Issue & Expiration Year

Figure 6-48: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Jardiance Tablet (US\$/SAR), January'2020

Figure 6-49: Jardiance - Recommended Minimum & Maximum Initial Dose for Adults (mg/day), January'2020

Figure 6-50: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Novonorm Tablet (US\$/SAR), January'2020

Figure 6-51: Repaglinide - Recommended Minimum & Maximum Initial Dose for Adults (mg/meal), January'2020

Figure 6-52: Pioglitazone - Recommended Minimum & Maximum Initial Dose for Adults (mg/meal), January'2020

Figure 6-53: Saudi Arabia - Price for 30 Tablet Supply of Actos 15mg & 30mg Tablet (US\$/SAR), January'2020

Figure 6-54: Saudi Arabia - Price for 30 Tablet Supply of Glacera 15mg, 30mg & 45mg Tablet (US\$/SAR), January'2020

Figure 6-55: Saudi Arabia - Price for 30 Tablet Supply of Glados 15mg, 30mg & 45mg Tablet (US\$/SAR), January'2020

Figure 6-56: Saudi Arabia - Price for 30 Tablet Supply of Acarose 50mg & 100mg Tablet (US\$/SAR), January'2020

Figure 6-57: Saudi Arabia - Price for 30 Tablet Supply of Glucobay 50mg & 100mg Tablet (US\$/SAR), January'2020

Figure 6-58: Acarbose - Recommended Initial & Maintenance Dose for Adults (mg/day), January'2020

Figure 6-59: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 250/1.25mg Tablet (US\$/SAR), January'2020

Figure 6-60: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 500/2.5mg Tablet (US\$/SAR), January'2020

Figure 6-61: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 500/5mg Tablet (US\$/SAR), January'2020

Figure 6-62: Saudi Arabia - Price for 30 Tablet Supply of Diamet 250/2.5mg, 500/2.5mg & 500/5mg Tablet (US\$/SAR), January'2020

Figure 6-63: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Glucovance 500/2.5mg Tablet (US\$/SAR), January'2020

Figure 6-64: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Glucovance 500/5mg Tablet (US\$/SAR), January'2020

Figure 6-65: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Amaryl M 2/500mg Tablet (US\$/SAR), January'2020

Figure 6-66: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Galvus Met 1000/50mg Tablet (US\$/SAR), January'2020

Figure 6-67: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Galvus Met 850/50mg Tablet (US\$/SAR), January'2020

Figure 6-68: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Jalra M 1000/50mg Tablet (US\$/SAR), January'2020

Figure 6-69: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Jalra M 850/50mg Tablet (US\$/SAR), January'2020

Figure 6-70: Saudi Arabia - Price for 56 Tablet Supply of 850/50mg & 1000/50mg Combinational Metformin/Sitagliptin Tablet (US\$/SAR), January'2020

Figure 6-71: Kombiglyze XR - Patent Issue & Expiration Year

Figure 6-72: Saudi Arabia - Price for 30 Tablet Supply of 500/5mg, 1000/5mg & 1000/2.5mg Kombiglyze XR Tablet (US\$/SAR), January'2020

Figure 6-73: Synjardy XR - Patent Issue & Expiration Year

Figure 6-74: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of 500/5mg, & 500/12.5mg Synjardy XR Tablet (US\$/SAR), January'2020

Figure 6-75: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of 1000/5mg, & 1000/12.5mg Synjardy XR Tablet (US\$/SAR), January'2020

Figure 6-76: Xigduo XR - Patent Issue & Expiration Year

Figure 6-77: Saudi Arabia - Price for 56 Tablet Supply & Price per Unit of 500/5mg Xigduo XR Tablet (US\$/SAR), January'2020

Figure 6-78: Saudi Arabia - Price for 28 Tablet 500/10mg, 1000/5mg & 1000/10mg Xigduo XR Tablet (US\$/SAR), January'2020

Figure 7-1: Lantus - Patent Issue & Expiration Year

Figure 7-2: Saudi Arabia - Price for 10ml Vial & Price per ml of Lantus (US\$/SAR), January'2020

Figure 7-3: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Lantus (US\$/SAR), January'2020

Figure 7-4: Saudi Arabia - Price for 10ml Vial & Price per ml of Humulin 70/30 (US\$/SAR), January'2020

Figure 7-5: Saudi Arabia - Price for 10ml Vial & Price per ml of Humulin N-NPH (US\$/SAR), January'2020

Figure 7-6: Saudi Arabia - Price for 10ml Vial & Price per ml of Humalog (US\$/SAR), January'2020

Figure 7-7: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Humalog (US\$/SAR), January'2020

Figure 7-8: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Humalog Mix 25 & 50 (US\$/SAR), January'2020

Figure 7-9: Saudi Arabia - Price for 10ml Vial & Price per ml of Mixtard 30 (US\$/SAR),

January'2020

Figure 7-10: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Mixtard 40 Novolet (US\$/SAR), January'2020

Figure 7-11: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Mixtard 50 HM Novolet (US\$/SAR), January'2020

Figure 7-12: Apidra - Patent Issue & Expiration Year

Figure 7-13: Saudi Arabia - Price for a 5 Vial Supply & Price per Vial of Apidra (US\$/SAR), January'2020

Figure 7-14: Saudi Arabia - Price for 10ml Vial & Price per ml of Insulatard (US\$/SAR), January'2020

Figure 8-1: Saudi Arabia - Diabetes Device Market Opportunity (US\$ Million), 2019-2025

Figure 8-2: Saudi Arabia - Number of Insulin Users (Million), 2019-2025

Figure 9-1: Saudi Arabia - Price for Supply of 90 & Price per unit of 8 mm BD Ultra-fine Insulin Syringe 31G, 1/2cc (US\$/SAR), January'2020

Figure 9-2: Saudi Arabia - Price for Supply of 100 & Price per unit of 8 mm BD Ultra-fine Insulin Syringe 31G, 3/10cc (US\$/SAR), January'2020

Figure 9-3: Saudi Arabia - Price for Supply of 90 & Price per unit of 6 mm BD Ultra-fine Insulin Syringe 31G, 3/10cc (US\$/SAR), January'2020

Figure 9-4: Saudi Arabia - Price for Supply of 90 & Price per unit of 0.5 inch BD Ultra-fine Insulin Syringe 30G, 3/10cc (US\$/SAR), January'2020

Figure 9-5: Saudi Arabia - Price for Supply of 100 Care Touch 28G, 29G, 30G & 31G Insulin Syringe (US\$/SAR), January'2020

Figure 9-6: Saudi Arabia - Insulin Syringe Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-7: Saudi Arabia - Insulin Syringe Consumption by 30% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-8: Saudi Arabia - Insulin Syringe Consumption by 40% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-9: Saudi Arabia - Insulin Syringe Consumption by 50% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-10: Saudi Arabia - Insulin Pen Market Opportunity (US\$ Million), 2019-2025

Figure 9-11: Commercially Available Insulin Pens

Figure 9-12: Saudi Arabia - Insulin Pen Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-13: Saudi Arabia - Insulin Pen Consumption by 30% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-14: Saudi Arabia - Insulin Pen Consumption by 40% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-15: Saudi Arabia - Insulin Pen Consumption by 50% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-16: Saudi Arabia - Insulin Pen Consumption by 60% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-17: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lispro Containing Humalog Kwikpen (US\$/SAR), January'2020

Figure 9-18: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lispro & Protamine Containing Humalog Kwikpen (US\$/SAR), January'2020

Figure 9-19: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Novomix Flexpen (US\$/SAR), January'2020

Figure 9-20: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Novorapid Flexpen (US\$/SAR), January'2020

Figure 9-21: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lemevir Flexpen (US\$/SAR), January'2020

Figure 9-22: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lantus Solostar (US\$/SAR), January'2020

Figure 9-23: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar (US\$/SAR), January'2020

Figure 9-24: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar 100,33mcg/ml (US\$/SAR), January'2020

Figure 9-25: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar 100,50mcg/ml (US\$/SAR), January'2020

Figure 9-26: Saudi Arabia - Price of Novopen 3, 4, 5 & Novopen Echo (US\$/SAR), January'2020

Figure 9-27: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 100units/ml Tresiba Flextouch pen (US\$/SAR), January'2020

Figure 9-28: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US\$/SAR), January'2020

Figure 9-29: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US\$/SAR), January'2020

Figure 9-30: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US\$/SAR), January'2020

Figure 9-31: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US\$/SAR), January'2020

Figure 9-32: Types of Insulin Pumps

Figure 9-33: Saudi Arabia - Insulin Pump Consumption by 5% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-34: Saudi Arabia - Insulin Pump Consumption by 10% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-35: Saudi Arabia - Insulin Pump Consumption by 15% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-36: Saudi Arabia - Insulin Pump Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-37: Saudi Arabia – Insulin Jet Injectors Consumption by 5% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-38: Saudi Arabia – Insulin Jet Injectors Consumption by 10% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-39: Saudi Arabia - Insulin Jet Injectors Consumption by 15% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-40: Saudi Arabia - Insulin Jet Injectors Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 9-41: Saudi Arabia - Insulin Jet Injectors Consumption by 25% of Total Insulin Delivery Device Users (000'), 2019-2025

Figure 10-1: Saudi Arabia - Commercially Available Glucose Monitoring Devices

Figure 10-2: Saudi Arabia - Glucose Monitoring Device Market Opportunity (US\$ Million), 2019-2025

Figure 10-3: Saudi Arabia - Price for Various Accu-Chek Blood glucose Monitoring Device (US\$/SAR), January'2020

Figure 10-4: Saudi Arabia - Price for Various Supplies of Accu-Chek Performa Test Strips (US\$/SAR), January'2020

Figure 10-5: Saudi Arabia - Price for 50 Strips & Price for Single Test Strip of Accu-Chek Active (US\$/SAR), January'2020

Figure 10-6: Saudi Arabia - Price for 50 Strips & Price for Single Test Strip of Accu-Chek Instant (US\$/SAR), January'2020

Figure 10-7: Saudi Arabia - Price for Supply of 50 & Price for Single Lancet of Accu-Chek Softclinx (US\$/SAR), January'2020

Figure 10-8: Saudi Arabia - Price for Supply of 102 & 204 Lancets of Accu-Chek Fastclinx (US\$/SAR), January'2020

Figure 10-9: Saudi Arabia - Price for Abbott's Freestyle Optimum Glucometer, Test Strip & Lancets (US\$/SAR), January'2020

Figure 10-10: Saudi Arabia - Price for Bayes Contour & Easy Max Glucometer (US\$/SAR), January'2020

Figure 10-11: Saudi Arabia - Price for 50 Lancet Supply and Price per unit of Bayes Contour Test Strips (US\$/SAR), January'2020

Figure 10-12: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 40% of Diagnosed Diabetics (Million), 2019-2025

Figure 10-13: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 50% of Diagnosed Diabetics (Million), 2019-2025

Figure 10-14: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 60% of Diagnosed Diabetics (Million), 2019-2025

Figure 10-15: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 70% of Diagnosed Diabetics (Million), 2019-2025

Figure 10-16: Saudi Arabia – Self-Regulating Blood Glucose Monitor Consumption by 80% of Diagnosed Diabetics (Million), 2019-2025

Figure 10-17: Saudi Arabia - Price of Freestyle Libre Sensor & Receiver (US\$/SAR), January'2020

Figure 10-18: Saudi Arabia - Price of Dexcom G5 Sensor, Receiver & Transmitter (US\$/SAR), January'2020

Figure 10-19: Saudi Arabia - Price of Dexcom G6 Sensor, Receiver & Transmitter (US\$/SAR), January'2020

Figure 10-20: Saudi Arabia - Price of a Supply of 3 Sensor & Price for Single Sensor of Dexcom G6 (US\$/SAR), January'2020

Figure 10-21: Saudi Arabia - Price for a Supply of 5 Sensor & Price for Single Sensor of Guardian Sensor 3 (US\$/SAR), January'2020

Figure 10-22: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 10% of Diagnosed Diabetics (000'), 2019-2025

Figure 10-23: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 20% of Diagnosed Diabetics (000'), 2019-2025

Figure 10-24: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 30% of Diagnosed Diabetics (000'), 2019-2025

Figure 10-25: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 40% of Diagnosed Diabetics (000'), 2019-2025

Figure 11-1: Saudi Arabia – Total Number of Clinical Trial v/s Diabetes related Trials, 2020

Figure 11-2: Saudi Arabia – Number of Diabetes related Clinical Trials by Development Phase, 2020

Figure 11-3: Saudi Arabia – Number of Diabetes related Clinical Trials by Development Phase, 2020

Figure 11-4: Saudi Arabia – Number of Clinical Trials by Status, 2019

Figure 13-1: Saudi Arabian Diabetes Market Drivers

Figure 13-2: Challenges for Saudi Arabia Diabetes Market

I would like to order

Product name: Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025

Product link: <https://marketpublishers.com/r/SBB581518884EN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SBB581518884EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970